Sirtris Pharmaceuticals' SIRT1 Activator Controls Glucose as well as a DPP-4 inhibitor in a Pre-Clinical Model of Type 2 Diabete
14 December 2007 - 2:00AM
Business Wire
Sirtris Pharmaceuticals, Inc. (NASDAQ: SIRT), a biopharmaceutical
company focused on discovering and developing small molecule drugs
to treat diseases of aging such as Type 2 Diabetes, is presenting
data today at the 2007 RBC Capital Markets Healthcare Conference on
The Pharmaceutical Sweet Spot: Diabetes And Obesity Treatments
Panel demonstrating that one of its new chemical entity (NCE) SIRT1
activators lowers plasma glucose and improves insulin sensitivity
in a pre-clinical model of Type 2 Diabetes as well as or better
than sitagliptin, a DPP-4 inhibitor. In addition, in an
intraperitoneal glucose tolerance test, Sirtris� SIRT1 activator
was shown to control glucose excursion as well as sitagliptin in
this pre-clinical model of Type 2 Diabetes. In contrast to DPP-4
inhibitors, which lower glucose, SIRT1 activation appears to both
lower glucose and also sensitize to insulin in these models. The
panel will be webcast live and can be accessed on the Sirtris
website, www.sirtrispharma.com, in the investor relations section.
A replay will be available approximately twenty-four hours after
the presentation and will be archived on the company�s website for
two weeks. About Sirtris Pharmaceuticals Sirtris Pharmaceuticals is
a biopharmaceutical company focused on discovering and developing
proprietary, orally available, small molecule drugs with the
potential to treat diseases associated with aging, including
metabolic diseases such as Type 2 Diabetes. Our drug candidates are
designed to mimic certain beneficial health effects of calorie
restriction, without requiring a change in eating habits, by
activation of sirtuins, a recently discovered class of enzymes that
control the aging process. The company's headquarters are in
Cambridge, Massachusetts. This press release contains
forward-looking statements within the meaning of the Private
Securities Litigation Reform Act of 1995. Such statements include,
but are not limited to, the potential therapeutic effects of SIRT1
activators for diseases of aging, such as Type 2 Diabetes and
disorders, such as MELAS, the progress and results of pre-clinical
studies of SIRT1 activators, and the potential of sirtuin
modulators to receive regulatory approval. These forward-looking
statements about future expectations, plans and prospects of
Sirtris Pharmaceuticals involve significant risks, uncertainties
and assumptions, including risks related to the lack of results
that would provide a basis for predicting whether any of the
Company�s product candidates will be safe or effective, or receive
regulatory approval, the possibility that results of pre-clinical
studies are not necessarily predictive of clinical trial results,
the Company's potential inability to initiate and complete
pre-clinical studies and clinical trials for its product
candidates, the fact that none of the Company's product candidates
has received regulatory approvals, the potential inability of
the�Company to gain market acceptance of the Company's product
candidates, and those other risks factors�that can be found in
the�Company's filings with the Securities and Exchange Commission.
Actual results may differ materially from those Sirtris
Pharmaceuticals contemplated by these forward-looking statements.
Sirtris Pharmaceuticals does not undertake to update any of these
forward-looking statements to reflect a change in its views or
events or circumstances that occur after the date of this release.
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Sierra Natl BK Tehachapi Calif (MM) (NASDAQ:SIRT)
Historical Stock Chart
From Jul 2023 to Jul 2024
Real-Time news about Sierra Natl BK Tehachapi Calif (MM) (NASDAQ): 0 recent articles
More Sirtris Pharmaceuticals, Inc. News Articles